PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Esomeprazole - Acid suppression (Adults)

PAD Profile : Esomeprazole - Acid suppression (Adults)

Keywords :
reflux, GORD, gastro-oesophageal reflux disease, indigestion, PPIs, Proton pump inhibitors, gastric ulcer, stomach ulcer, dyspepsia
Brand Names Include :
Nexium

Traffic Light Status

Status 1 of 3.

Status :
Green (see narrative)
Important
Formulations :
  • Capsules
Important Information :
Lansoprazole capsules are the preferred option. Esomeprazole 40mg restricted to short-term use or for Zollinger-Ellison syndrome.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 3.

Status :
Non Formulary
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 3 of 3.

Status :
Green (see narrative)
Important
Formulations :
  • Granules
Important Information :
Lansoprazole oro-dispersible 1st-line. Esomeprazole is 3rd-line. Restricted to patients with swallowing difficulties or with large bore enteral feeding tube when other options are not clinically appropriate. Do not use in tubes less than 6F.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :

Most (but not all) brands of esomeprazole tablets, capsules and granules for oral suspension are licensed for administration via gastric tubes. They will disperse in water for administration. For patients with fine-bore enteral tubes, consider switching to lansoprazole orodispersible tablets, which have smaller micro-granules

Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 May 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Change to traffic light status:

Esomeprazole capsules are now considered Green (3rd line).

The decision of September 2022 has been superceded BUT lansoprazole capsules remain the preferred PPI in patients with and without swallowing difficulties and in patients with an enteral feeding tube.

Note - 40mg esomeprazole capsules are restricted for short-term use prior to step down OR Zollinger-Ellison syndrome

07 September 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed esomeprazole capsules can continue to be prescribed for patients with no swallowing difficulty but should not be started in any new patients - alternatives are available as per below.


Most (but not all) brands of esomeprazole tablets, capsules and granules for oral suspension are licensed for administration via gastric tubes. They will disperse in water for administration. For patients with fine-bore enteral tubes, consider switching to lansoprazole orodispersible tablets, which have smaller micro-granules

For people with no swallowing difficulties:

  • 1st Line: Lansoprazole capsules/Omeprazole capsules
  • 2nd line: Pantoprazole tablets (Suitable for patients that cannot have animal-derived products) 
  • 2nd line: Rabeprazole tablets (Suitable for patients that cannot have animal-derived products)
  • 3rd line: Esomeprazole capsules – not for new initiation

For patients who cannot swallow tablets/have swallowing difficulties:

  • 1st Line: lansoprazole orodispersible tablets
  • 2nd line: lansoprazole capsules/omeprazole capsules (opened, and granules dispersed in water/yoghurt/apple puree)
  • 3rd line: esomeprazole granule sachets

For patients with enteral feeding tubes:

  • 1st line: lansoprazole orodispersible tablets
  • 2nd line: lansoprazole capsules
  • 3rd line: esomeprazole granule sachets (do not use if tube is less than 6F)

Associated BNF Codes

01. Gastro-Intestinal System
01.03.05. Proton pump inhibitors
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More